In thyroid eye disease, a type of immune cell that normally keeps other immune cells in check is less active and less numerous, allowing the immune system to attack the tissues around the eyes.
Claim Context
Regulatory T cells (Tregs) are reduced in number and function in patients with thyroid eye disease, contributing to loss of immune tolerance and uncontrolled autoimmune attack on orbital tissues.
“Research analyzing peripheral blood and orbital tissue samples from patients revealed that the proportion of Tregs in their peripheral blood was significantly lower than in healthy individuals, with markedly diminished ability to suppress effector T cell function. This allows self-reactive T cells to evade regulatory control, abnormally activate, and attack orbital tissues, triggering inflammatory responses and tissue damage.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could quantify the pooled difference in Treg frequency and suppressive function between TED patients and healthy controls across all published studies.
A systematic review and meta-analysis of all flow cytometry studies measuring CD4+CD25+FoxP3+ Treg frequency and in vitro suppressive capacity in peripheral blood or orbital tissue from TED patients versus healthy controls, stratified by disease activity.
A trial could determine whether expanding Tregs reduces TED activity.
A double-blind RCT of 60 patients with active TED, randomized to receive autologous ex vivo-expanded Tregs (1×10^6/kg) via IV infusion versus placebo, with primary outcome of CAS reduction at 12 weeks and secondary outcomes of Treg frequency and TRAb levels.
A cohort study could determine whether low Treg levels predict TED onset in Graves' disease patients.
A prospective cohort of 400 patients with newly diagnosed Graves' disease, measuring baseline Treg frequency and function, followed for 24 months to assess incidence of TED, adjusting for TRAb, smoking, and HLA status.
A case-control study could compare Treg levels in TED patients versus Graves' patients without eye disease.
A matched case-control study comparing Treg frequency (CD4+CD25+FoxP3+) and suppressive function in peripheral blood from 80 TED patients and 80 Graves' patients without ophthalmopathy, matched for age, sex, TRAb titer, and disease duration.
A cross-sectional study could describe Treg levels in TED patients at a single time point.
A cross-sectional analysis of peripheral blood from 150 TED patients and 75 healthy controls, measuring Treg frequency via flow cytometry and correlating with CAS and proptosis.